Cardiorenal Syndrome: Pathophysiology, Verification, Approaches to Treatment
DOI:
https://doi.org/10.22141/2307-1257.0.1.2012.176443Abstract
No abstract
Downloads
References
Lindner A., Charra B., Sherrard D.J., Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis // N. Engl. J. Med. — 1974. — 290. — 697-701.
Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease // Am. J. Kidney. Dis. — 1998. — 32: 112-119.
Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III) // J. Am. Soc. Nephrol. — 2002. — 13(5). — 1338-1349.
Sarnak M.J., Levey A.S., Schoolwerth A.C. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention // Circulation. — 2003. — 108. — 2154-2169.
Heywood J.T. The cardiorenal syndrome: lessons from the ADHERE database and treatment options // Heart Fail Rev. — 2004. — 9. — 195-201.
Chadban S.J., Briganti E.M., Kerr P.G., Dunstan D.W., Welborn T.A., Zimmet P.Z., Atkins R.C.: Prevalence of kidney damage in Australian adults: The AusDiab kidney study // J. Am. Soc. Nephrol. — 2005. — 14[Suppl]. — 131-138.
Foley R., Murray A., Li S. et al. Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999 // J. Am. Soc. Nephrol. — 2005. — 16. — 489-495.
McCullough P.A., Li S., Jurkovitz C.T. et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004 // Am. J. Kidney Dis. — 2008. — 51(4 Suppl 2). — 38-45.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification // Am. J. Kidney Dis. — 2002. — 39(2 suppl 1). — S1-S266.
Моисеев В.С., Кобалава Ж.Д. Кардиоренальные синдромы (патогенетические, клинико-диагностические и терапевтические аспекты) // Терапевтический архив. — 2011. — № 12. — С. 5-11.
Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний // Вестник РАМН. — 2003. — № 11. — С. 50-55.
Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек // Терапевтический архив. — 2004. — № 6. — С. 39-46.
Palevsky P.M. Epidemiology of acute renal failure: the tip of the iceberg // Clin. J. Am. Soc. Nephrol. — 2006. — 1. — 6-7.
Mehta R.L., Kellum J.A., Shah S.V. et al. Acute Kidney Injury Network (AKIN): report of an initiative to improve outcomes in acute kidney injury // Crit. Care. — 2007. — 11. — R31.
Bellomo R., Ronco C., Kellum J.A. et al. and the ADQI workgroup. Acute renal failure — definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group // Crit. Care. — 2004. — 8. — R204-R212.
Ledoux P. Cardiorenal syndrome // Avenir. Med. — 1951. — 48(8) . — 149-153.
Palaniappan L., Carnethon M., Formann S.P. Association between microalbuminuria and the metabolic syndrome: NHANES III // Am. J. Hypertens. — 2003. — 16(11) . — 952-958.
Silverberg D.S. Outcomes of anaemia management in renal insufficiency and cardiac disease // Nephrol. Dial. Transplant. — 2003. — 18 (suppl 2) . — ii7-ii12.
Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade // J. Hypertens. — 2005. — 23(suppl 1). — S9-S17.
The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // EНJ. — 2007. — 28. — 1462-1536.
Визир В.А., Березин А.Е. Кардиоренальный синдром // Артериальная гипертензия. — 2011. — № 2(16). — С. 100–109.
Кобалава Ж.Д., Ефремовцева М.А., Виллевальде С.В. Кардиоренальные синдромы // Клиническая нефрология. — 2011. — № 6. — С. 9-15.
Liang K.V., Williams A.W., Greene E.L., Redfield M.M.
Acute decompensated heart failure and the cardiorenal syndrome // Crit. Care Med. — 2008. — 36. — S75-88.
Ronco C., McCullough P., Anker S. et al.Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative // Eur. Heart. J. — 2010. — 31. — 703-711.
Latchamsetty R., Fang J., Kline-Rogers E. et al. Prognostic Value of Transient and Sustained Increase in In-Hospital Creatinine on Outcomes of Patients Admitted With Acute Coronary Syndrome // Am. J. Cardiol. — 2007. — 99(7). — 939-942.
Jose P., Skali H., Anavekar N. et al. Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction // J. Am. Soc. Nephrol. — 2006. — 17. — 2886-2891.
Berl T., Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment // Clin. J. Am. Soc. Nephrol. — 2006. — 1. — 8-18.
Gottlieb S.S., Abraham W., Butler J. et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure // J. Card. Fail. — 2002. — 8. — 136-141.
Krumholz H.M., Chen Y.T., Vaccarin. V. et al. Correlates and impact on outcomes of worsening renal function in patients ≥ 65 years of age with heart failure // Am. J. Card. — 2000. — 85. — 1110-1113.
Cowie M.R., Komajda M., Murray-Thomas T. et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH) // EHJ. — 2006. — 27. — 1216-22.
Smith G.L., Vaccarino V., Kosiborod M. et al. Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure? // J. Card. Fail. — 2003. — 9. — 13-25.
Ronco C., Bellomo R., McCullough P.A. Cardiorenal Syndromes in Critical Care // Contrib. Nephrol. — Basel, Karge, 2010. — Vol. 165.
Adams K.F., Fonarow G.C., Emerman C.L. et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE) // Am. Heart. J. — 2005. — 149. — 209-216.
Fonarow G.C., Stough W.G., Abraham W.T. et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry // J. Am. Coll. Cardiol. — 2007. — 50. — 768-777.
Jose P., Skali H., Anavekar N. et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction // J. Am. Soc. Nephrol. — 2006. — 17. — 2886-2891.
Goldberg A., Hammerman H., Petcherski S. et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction // Am. Heart. J. — 2005. — 150. — 330-307.
Costanzo M.R., Guglin M.E., Saltzberg M.T. et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure // J. Am. Coll. Cardiol. — 2007. — 13. — 49. — 675-683.
Tessone A., Gottlieb S., Barbash I.M. et al. Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency // Cardiology. — 2007. — 108. — 193-199.
Ahmed A., Rich M.W., Sanders P.W. et al. Chronic Kidney Disease Associated Mortality in Diastolic Versus Systolic Heart Failure: A Propensity Matched Study // Am. J. Cardiol. — 2007. — 99. — 393-398.
Campbell R.C., Sui S., Filippatos G. et al. Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study // Nephrol. Dial. Transplant. — 2009. — 24. — 186-193.
Forman D.E., Butler J., Wang Y. et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure // J. Am. Coll. Cardiol. — 2004. — 43. — 61-67.
Hillege H.L., Nitsch D., Pfeffer M.A. et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure // Circulation. — 2006. — 113. — 671-678.
Dimopoulos K., Diller G.P., Koltsida E. et al. Prevalence, Predictors, and Prognostic Value of Renal Dysfunction in Adults With Congenital Heart Disease // Circulation. — 2008. — 117. — 2320-2328.
Bhatia R.S., Tu J.V., Lee D.S. et al. Outcome of heart failure with preserved ejection fraction in a population-based study // N. Engl. J. Med. — 2006. — 355. — 260-269.
Despres J.-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk // Eur. Heart. J. — 2006. — 8(suppl. B). — B4-B12.
Lea J.P., Greene E.L., Nicholas S.B. et al. Cardiorenal metabolic syndrome in the african diaspora: rationale for including chronic kidney disease in the metabolic syndrome definition // Ethn Dis. — 2009. — 19(Suppl 2). — 11-14.
Roghi A., Savonitto S., Cavallini C. et al. Impact of acute renal failure following percutaneous coronary intervention on long-term mortality // J. Cardiovasc. Med. — 2008. — 9. — 375-381.
Lassnigg A., Schmid E.R., Hiesmayr M. et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? // Crit. Care Med. — 2008. — 36. — 1129-1137.
Hirsch A.T., Haskal Z.J., Hertzer N.R. et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) // J. Am. Coll. Cardiol. — 2006. — 47. — e1-192.
Coresh1 J., Stevens L., Levey A. Chronic kidney disease is common: What do we do next? // Nephrol. Dial. Transplant. — 2008. — 23(8). — 1122-1125.
McClellan W. The epidemic of renal disease — what drives it and what can be done? // Nephrol. Dial. Transplant. — 2006. — 21(6) . — 1461-1464.
Levin A., Foley R.N. Cardiovascular disease in chronic renal insufficiency // Am. J. Kidney Dis. — 2000. — 36. — S24-30.
Jie K.E., Verhaar M.C., Cramer M.J. et al. Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors // Am. J. Renal. Physiol. — 2006. — 291. — F932-44.
Palazzuoli A., Silverberg D.S., Iovine F. et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome // Am. Heart. J. — 2007. — 154. — 645. — e9-15.
House A.A., Haapio M., Lassus J. et al. Therapeutic strategies for heart failure in cardiorenal syndromes // Am. J. Kidney. Dis. — 2010. — 56. — 759-773.
Roy P., Bouchard J., Amyot R., Madore F. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients // Am. J. Kidney. Dis. — 2006. — 48. — 645-51.
Ko D.T., Juurlink D.N., Mamdani M.M. et al. Appropriateness of spironolactone prescribing in heart failure patients: a populationbased study // J. Card. Fail. — 2006. — 12. — 205-210.
Bagshaw S.M., Lapinsky S., Dial S. et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy // Intensive. Care. Med. — 2009. — 35. — 871-881.
Oppert M., Engel C., Brunkhorst F.M. et al. Acute renal failure in patients with severe sepsis and septic shock — a significant independent risk factor for mortality: results from the German Prevalence Study // Nephrol. Dial. Transplant. — 2008. — 23. — 904-909.
Ammann P., Maggiorini M., Bertel O. et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes // J. Am. Coll. Cardiol. — 2003. — 41. — 2004-2009.
Bongartz L.G., Cramer M.J., Doevendans P.A. et al. The severe cardiorenal syndrome: Guyton revisited // Eur. Heart. J. — 2005. — 26. — 11-17.
Brewster U.C., Setaro J.F., Perazella M.A. The renin-angiotensinaldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states // Am. J. Med. Sci. — 2003. — 326. — 15-24.
Silverberg D.S., Wexler D., Blum M. et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations // J. Am. Coll. Cardiol. — 2000. — 35. — 1737-1744.
Levin A., Thompson C.R., Ethier J. et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin // Am. J. Kidney. Dis. — 1999. — 34. — 125-134.
Ronco C., Cruz D.N. Biomarkers in cardio-renal syndromes (Rassegna) // Altri Contributi LigandAssay. — 14(4). — 2009. — 340-349.
Austin W.J., Bhalla V., Hernandez-Arce I. et al. Correlation and prognostic utility of B-type natriuretic peptide and its aminoterminal fragment in patients with chronic kidney disease // Am. J. Clin. Pathol. — 2006. — 126. — 506-512.
Needham D.M., Shufelt K.A., Tomlinson G. et al. Troponin I and T levels in renal failure patients without acute coronary syndrome: a systematic review of the literature // Can. J. Cardiol. — 2004. — 20. — 1212-1218.
Abbas N.A., Jhon R.I., Webb M.C. et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease // Clin. Chem. — 2005. — 51. — 2059-2066.
Roberts M.A., MacMillan N., Hare D.L. et al. Cardiac troponin levels in asymptomatic patients on the renal transplant waiting list // Nephrology (Carlton). — 2006. — 11. — 471-476.
Braunwald E. Biomarkers in heart failure // N. Engl. J. Med. — 2008. — 358. — 2148-59.
Han W.K., Bonventre J.V. Biologic markers for the early detection of acute kidney injury // Curr. Opin. Crit. Care. — 2004. — 10. — 476-482.
Ronco C. NGAL: an emerging biomarker of acute kidney injury // Int. J. Artif. Organs. — 2008. — 31. — 199-200.
VandeVoorde R.G., Katlman T.I., Ma Q. et al. Serum NGAL and cystatin C as predictive biomarkers for acute kidney injury // J. Am. Soc. Nephrol. — 2006. — 17. — 404A.
Han W.K., Bailly V., Abichandani R., Thadhani R., Bonventre J.V. Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury // Kidney Int. — 2002. — 62. — 237-244.
Parikh C.R., Devarajan P. New biomarkers of acute kidney injury // Crit Care Med. — 2008. — 36(4 Suppl). — 159-165.
Price R.G. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity // Clin. Nephrol. — 1992. — 38(Suppl 1). — 14-19.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC // European Heart Journal. — 2012. — 33. — 1787-1847.
Leier C.V. Renal roadblock in managing low output heart failure // Critical Care Medicine. — 2004. — 32(5) . — 1228-1229.
Cooper H.A., Dries D.L., Davis C.E. et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction // Circulation. — 1999. — 100. — 1311-1315.
Ali F., Guglin M., Vaitkevicius P., Ghali J.K. Therapeutic potential of vasopressin receptor antagonists // Drugs. — 2007. — 67(6) . — 847-858.
Greenberg A., Verbalis J.G. Vasopressin receptor antagonists // Kidney Int. — 2006. — 69. — 2124-2130.
Veeraveedu P.T., Watanabe K., Ma M., Palaniyandi S.S., Yamaguchi K., Kodama M., Aizawa Y. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure // Biochem. Pharmacol. — 2008. — 75(6). — 1322-1330.
Costello-Boerrigter L.C., Boerrigter G., Burnett J.C. Jr. V2-receptor antagonism with tolvaptan in heart failure // Expert Opin. Investig. Drugs. — 2007. — 16(10) . — 1639-1647.
Goldsmith S.R. Vasopressin: a therapeutic target in congestive heart failure? // J. Cardiac. Failure. — 1999. — 5. — 347-356.
Greenberg А. Tolvaptan, an Oral Vasopressin V2-Receptor Antagonist for Heart Failure? // Am. J. Kidney Diseases. — 2007. — 50(6). — 904-907.
Givertz M.M., Massie B.M., Fields T.K., Pearson L.L., Dittrich H.C. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance // J. Am. Coll. Cardiol. — 2007. — 50(16). — 1551-1560.
Remme W.J. Positive inotropes: a new horizon or still a dead end? // Cardiovasc. Drugs Ther. — 2001. — 15. — 375-377.
Thackray S., Easthaugh J., Freemantle N. et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure — a meta regression analysis // Eur. J. Heart Fail. — 2002. — 4. — 515-529.
Felker G.M., Benza R.L., Chandler A.B. et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study // J. Am. Coll. Cardiol. — 2003. — 41(6). — 997-1003.
Cleland J.G., Freemantle N., Coletta A.P., Clark A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE // Eur. J. Heart Fail. — 2006. — 8. — 105-110.
Stevenson L.W. Clinical use of inotropic therapy for heart failure // Circulation. — 2003. — 108. — 367-372.
Yokoshiki H., Katsube Y., Sunagawa M. et al. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes // Eur. J. Pharmacol. — 1997. — 333. — 249-259.
Follath F., Cleland J.G., Just H. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double blind trial // Lancet. — 2002. — 360. 196-202.
Slawsky M.T., Colucci W.S., Gottlieb S.S. et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators // Circulation. — 2000. — 102. — 2222-2227.
Mebazaa A., Nieminen M.S., Packer M. et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial // J. Am. Med. Association. — 2007. — 297(17). — 1883-1891.
Lilleberg J., Ylonen V., Lehtonen L., Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies // Scand. Cardiovasc. J. — 2004. — 38. — 80-84.
Moiseyev V.S., Poder P., Andrejevs N. et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) // Eur. Heart J. — 2002. — 23. — 1422-1432.
McMurray J., Pitt B., Latini R. et al. Effects of the oral direct inhibitor aliskiren in patients with symptomatic heart failure // Circ. Heart Fail. — 2008. — 11. — 17-24.
Butler J., Emerman C., Peacock W.F. et al. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure // Nephrol. Dial. Transplant. — 2004. — 19. — 391-399.
Jensen K.T., Carstens J., Pedersen E.B. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans // Am. J. Physiol. — 1998. — 274: F63-F72.
Fonarow G.C. The treatment targets in acute decompensated heart failure // Rev. Cardiovasc. Med. — 2001. — 2(Suppl. 2). — S7-S12.
Keating G.M., Goa K.L. Nesiritide: a review of its use in acute decompensated heart failure // Drugs. — 2003. — 63. — 47-70.
Hillege H., Van Gilst W., de Zeeuw D. et al. Renal function as a predictor of prognosis in chronic heart failure // Heart Fail. Monit. — 2002. — 2. — 78-84.
Jensen K.T., Eiskjaer H., Carstens J. et al. Renal effects of brain natriuretic peptide in patients with congestive heart failure // Clin Sci. — 1999. — 96. — 5-15.
VMAC Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial // JAMA. — 2002. — 287. — 1531-1540.
Cataliotti A., Boerrigter G., Costello-Boerrigter L.C. et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure // Circulation. — 2004. — 109. — 1680-1685.
O'Connor C.M., Starling R.C., Hernandez A.F. et al. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure // N. Engl. J. Med. — 2011. — 365. — 32-43.
Bart B.A., Boyle A., Bank A.J. et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the relief for acutely fluid-overloaded patients with decompensated congestive heart failure (RAPID-CHF) trial // J. Am. Coll. Cardiol. — 2005. — 46(11) . — 2043-2046.
Costanzo M.R., Guglin M.E., Saltzberg M.T. et al. Ultrafiltration versus intravenous diuretics for patients hospita¬lized for acute decompensated heart failure // J. Am. Coll. Cardiol. — 2007. — 49(6). — 675-683.
Bart B.A., Goldsmith S.R., Lee K.L. et al. Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network // J. Card. Fail. — 2012 Mar. — 18(3). — 176-182.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 G.V. Dzyak, P.A. Kaplan
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 2307-1257
ISSN 2307-1265
